Literature DB >> 9794904

Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.

W Nolte1, J Wiltfang, C Schindler, H Münke, K Unterberg, U Zumhasch, H R Figulla, G Werner, H Hartmann, G Ramadori.   

Abstract

A prospective study of hepatic encephalopathy (HE) including neuropsychiatric and psychometric evaluation, electroencephalography, and determination of arterial ammonia levels was performed in 55 cirrhotic patients treated consecutively by transjugular intrahepatic portosystemic shunt (TIPS). The cumulative HE rate increased from 23.6% within the 3-month interval before TIPS to 50. 9% within the first 3-month interval post-TIPS (P = .003). Significant and independent predictors of HE post-TIPS were the presence of HE pre-TIPS and reduced liver function. The cumulative HE rate declined in the second 3-month interval post-TIPS and reached the pre-TIPS level. Chronic forms of HE exceeding grade I were not observed. In a subgroup of 22 nonencephalopathic TIPS patients, the prevalence of subclinical HE did not change after TIPS. Among individual psychometric tests, the block design test gave the highest proportion of pathological results (about 50%), whereas selective reminding gave the lowest (10%-25%). Electroencephalography (EEG) showed a temporary increase of pathological results at 1 month after TIPS, when patients with overt HE (grade I) were included (proportion of 21.1% before vs. 57.1%, P = .005). Arterial ammonia concentration increased from a mean of 94 +/- 26 microgram/dL to 140 +/- 28 microgram/dL at 3 months after TIPS (P < .001). Elevated ammonia levels persisted. TIPS led to a temporary increase of HE incidence within 3 months. The decline of the HE rate beyond 3 months despite a sustained increase of arterial ammonia levels could not entirely be explained by reduction of shunt flow, nor by alteration of liver function. Instead, cerebral adaptation to gut-derived neurotoxins might be anticipated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794904     DOI: 10.1002/hep.510280508

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration.

Authors:  M Plauth; A E Roske; P Romaniuk; E Roth; R Ziebig; H Lochs
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 3.  Psychiatric aspects of portal-systemic encephalopathy.

Authors:  J Wiltfang; W Nolte; K Weissenborn; J Kornhuber; E Rüther
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 4.  The brain following transjugular intrahepatic portosystemic shunt: the perspective from neuroimaging.

Authors:  Hui Juan Chen; Gang Zheng; Julian L Wichmann; U Joseph Schoepf; Guang Ming Lu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2015-09-24       Impact factor: 3.584

Review 5.  Hepatic encephalopathy: a dynamic or static condition.

Authors:  Charmaine A Stewart; Jane Cerhan
Journal:  Metab Brain Dis       Date:  2005-09       Impact factor: 3.584

Review 6.  Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Davide Roccarina; Francesca Romana Ponziani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

7.  Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Silvia Nardelli; Stefania Gioia; Chiara Pasquale; Ilaria Pentassuglio; Alessio Farcomeni; Manuela Merli; Filippo Maria Salvatori; Leandra Nikolli; Sabrina Torrisi; Francesca Greco; Valeria Nicoletti; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2016-03-01       Impact factor: 10.864

8.  No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Oliviero Riggio; Silvia Nardelli; Chiara Pasquale; Ilaria Pentassuglio; Stefania Gioia; Eugenia Onori; Camilla Frieri; Filippo Maria Salvatori; Manuela Merli
Journal:  Metab Brain Dis       Date:  2015-08-20       Impact factor: 3.584

9.  Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.

Authors:  Hui Xue; Meng Zhang; Jack Xq Pang; Fei Yan; Ying-Chao Li; Liang-Shan Lv; Jia Yuan; Muna Palikhe; Wei-Zhi Li; Zhi-Lun Wang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

10.  Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.

Authors:  Papia Mondal; Surendra Kumar Trigun
Journal:  Metab Brain Dis       Date:  2014-05-08       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.